Taysha Gene Therapies Target of Unusually Large Options Trading (NASDAQ:TSHA)

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) was the target of some unusual options trading on Thursday. Traders purchased 1,583 call options on the stock. This is an increase of 358% compared to the average volume of 346 call options.

Taysha Gene Therapies Trading Up 53.5%

NASDAQ:TSHA opened at $4.88 on Friday. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -14.35 and a beta of 0.99. The company has a debt-to-equity ratio of 0.17, a quick ratio of 12.48 and a current ratio of 12.48. Taysha Gene Therapies has a 1 year low of $1.05 and a 1 year high of $4.92. The business has a fifty day moving average of $2.98 and a 200-day moving average of $2.45.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). The company had revenue of $1.99 million for the quarter, compared to the consensus estimate of $1.61 million. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. Equities analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Insider Transactions at Taysha Gene Therapies

In other Taysha Gene Therapies news, insider Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total value of $646,000.00. Following the completion of the transaction, the insider owned 1,006,439 shares of the company’s stock, valued at $3,250,797.97. The trade was a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 3.78% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TSHA. Jane Street Group LLC increased its stake in shares of Taysha Gene Therapies by 57.6% during the fourth quarter. Jane Street Group LLC now owns 169,575 shares of the company’s stock valued at $293,000 after acquiring an additional 62,003 shares during the period. Ameriprise Financial Inc. bought a new position in Taysha Gene Therapies during the 4th quarter valued at $40,000. BNP Paribas Financial Markets acquired a new position in shares of Taysha Gene Therapies during the 4th quarter valued at $41,000. Millennium Management LLC bought a new stake in shares of Taysha Gene Therapies in the 4th quarter worth $262,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Taysha Gene Therapies by 32.3% in the fourth quarter. ProShare Advisors LLC now owns 59,076 shares of the company’s stock valued at $102,000 after buying an additional 14,418 shares during the period. 77.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on TSHA shares. Needham & Company LLC raised their price target on shares of Taysha Gene Therapies from $8.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday. Bank of America assumed coverage on shares of Taysha Gene Therapies in a research note on Friday, July 11th. They set a “buy” rating and a $8.00 price objective on the stock. Wells Fargo & Company raised their target price on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the stock an “overweight” rating in a report on Wednesday, August 13th. Robert W. Baird upped their target price on Taysha Gene Therapies from $7.00 to $12.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Chardan Capital increased their price target on Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a “buy” rating in a research report on Tuesday, August 12th. Nine analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Taysha Gene Therapies has a consensus rating of “Buy” and an average price target of $9.00.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.